<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278382</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02682</org_study_id>
    <secondary_id>GCC0508</secondary_id>
    <secondary_id>CDR0000456442</secondary_id>
    <nct_id>NCT00278382</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 2 Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of cancer cells by blocking blood flow to the cancer and by&#xD;
      blocking some of the enzymes needed for cell growth. This phase II trial is studying how well&#xD;
      sorafenib works in treating patients with chemosensitive recurrent aggressive non-Hodgkin's&#xD;
      lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the overall response rate, including complete and partial responses, in patients&#xD;
      with chemosensitive, relapsed, aggressive, non-Hodgkin's lymphoma treated with sorafenib.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine progression-free and overall survival of patients treated with this drug.&#xD;
&#xD;
      II. Determine response duration in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (complete and partial response)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be calculated as the percent of evaluable patients whose best response is a CR or PR. The exact binomial method will be used to determine the confidence interval of response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Kaplan-Meier product-limit method will be used in analysis of survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Kaplan-Meier product-limit method will be used in analysis of time to disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed aggressive* non-Hodgkin's lymphoma by&#xD;
             excisional-node biopsy or core needle biopsy and bone marrow biopsy, including 1 of&#xD;
             the following types:&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
               -  Primary mediastinal large B-cell lymphoma&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma (T-cell or null-cell type)&#xD;
&#xD;
          -  Recurrent disease&#xD;
&#xD;
          -  Patients must have received ≥ 1 induction regimen containing anthracyclines (e.g.,&#xD;
             CHOP [with or without rituximab] or R-EPOCH)&#xD;
&#xD;
          -  Chemosensitive disease at the time of relapse&#xD;
&#xD;
               -  Patients who responded with a complete or partial remission that lasted at least&#xD;
                  8 weeks after their last chemotherapy regimen are considered chemosensitive&#xD;
&#xD;
          -  Measurable disease, defined as a lymph node or a nodal mass of &gt; 1 cm in its longest&#xD;
             transverse diameter on CT scan&#xD;
&#xD;
          -  Ineligible for, refused, or relapsed after stem cell transplant (for patients with&#xD;
             non-mantle cell lymphoma)&#xD;
&#xD;
          -  No known brain metastases, including meningeal involvement&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2&#xD;
&#xD;
          -  Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No uncontrolled illness&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to sorafenib&#xD;
&#xD;
          -  No known positive HIV serology&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No swallowing dysfunction that would prevent ingestion of pills&#xD;
&#xD;
          -  No hemorrhagic diathesis&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No psychiatric or social situation that would limit compliance with study requirements&#xD;
&#xD;
          -  No poorly controlled medical condition that would seriously complicate compliance with&#xD;
             this study&#xD;
&#xD;
          -  Patients with inflammatory or exfoliative skin disease are excluded (regardless of the&#xD;
             extent of the involvement) unless the skin condition is lymphoma related&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Previous treatment-related toxic effects should be resolved to grade 1 or better&#xD;
&#xD;
          -  No chemotherapy or radiation therapy within the past 4 weeks&#xD;
&#xD;
               -  6 weeks for nitrosoureas or mitomycin C&#xD;
&#xD;
          -  No prior antibody therapy for at least 3 months&#xD;
&#xD;
          -  Prior radiation for localized disease or total body irradiation as part of a&#xD;
             conditioning regimen prior to stem cell transplant allowed&#xD;
&#xD;
          -  Prior radio-immunotherapy allowed&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
               -  Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial&#xD;
                  access devices are acceptable provided that the requirements for PT, INR, and PTT&#xD;
                  are met&#xD;
&#xD;
          -  No concurrent use of another investigational agent&#xD;
&#xD;
          -  No concurrent use of the following drugs: phenytoin, carbamazepine, phenobarbital,&#xD;
             rifampin, or Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meyer Heyman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

